

Research Ethics Committee Reference		Study Title	Recruitment Target	Recruitment End Date	Study Status	Performance Against Target
12/NW/0585		Trastuzumab Emtansine (TDM1) (GATSBY)	2	31/07/2014	Closed - In Follow Up	Target Met
13/YH/0021		MCRN221 MCI-196-E16	2	31/07/2014	Withdrawn	Withdrawn
GTAC185		PROSTVAC-V/F +/- GM-CSF in prostate cancer	5	31/08/2014	Closed - In Follow Up	Target Met
14/EM/0001		CCRN 2875 (Age-related macular degeneration)	5	05/09/2014	Closed - Follow Up Complete	Target Met
13/NE/0294		ROCHE PHASE I SINGLE ASCENDING DOSE Study of RO6867461 in wAMD	3	30/12/2014	Closed - Follow Up Complete	Target Met
10/H0406/46		ABBOTT 880 CCRN 282 (Inactive uveitis)	4	31/12/2014	Closed - Follow Up Complete	Target Met
12/LO/0080		OCTAVE A3921095: 007: Oral CP690,550 as an Induction Therapy for Ulcerative Colitis	5	31/12/2014	Closed - In Follow Up	Target Not Met
12/LO/0082		OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of Ulcerative Colitis	5	31/12/2014	Closed - In Follow Up	Target Not Met
13/YH/022		MCRN223 MCI-196-E15 Extension Study Evaluating Colestilan	2	31/12/2014	Withdrawn	Withdrawn
13/EE/0263		MASTER II Trial	20	31/12/2014	Closed - In Follow Up	Target Met
12/EE/0071		CCRN 923 (Ascites)	6	31/12/2014	Closed - In Follow Up	Target Met
12/SC/0309		NCRN371 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia	1	31/01/2015	Closed - In Follow Up	Target Met
10/H1003/120		Intravenous zanamivir versus oral oseltamivir in hospitalised influenza (NAI114373 - ZORO)	2	27/02/2015	Closed - Follow Up Complete	Target Not Met
13/YH/0020		MCRN222 (MCI-196-E14)	1	28/02/2015	Withdrawn	Withdrawn
14/SC/0100		JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With JETREA® for Vitreomacular Traction	5	06/03/2015	Withdrawn	Withdrawn
13/YH/0136		CCRN 2173 (AI Liver Decompensation)	2	30/03/2015	Closed - Follow Up Complete	Target Not Met
13/NW/0320		MCRN235 (WA28117)	2	31/03/2015	Closed - In Follow Up	Target Met
13/LO/0720		NCRN492 - NEMO-MEK162 vs Dacarbazine in NRAS mutation positive melanoma patients	2	31/03/2015	Closed - In Follow Up	Target Not Met
14/NW/0008		GO-COLITIS	6	31/03/2015	Withdrawn	Withdrawn
14/EE/1001		OTO-104 in Meniere's Disease	5	17/04/2015	Closed - In Follow Up	Target Met
12/LO/0081		OCTAVE A3921096: 008: Oral CP-690, 550 as Maintenance Therapy for Ulcerative Colitis	3	30/04/2015	Closed - In Follow Up	Target Not Met
14/SW/0079		CCRN - 3308 The DEFLECT III Trial	6	30/04/2015	Closed - In Follow Up	Target Met
13/WA/0269		CCRN 771 (Endometriosis-related pain)	6	08/05/2015	Closed - In Follow Up	Target Not Met
10/H1308/84		NCRN252 - Nilotinib in paediatric Ph+ CML/ALL	1	31/05/2015	Closed - In Follow Up	Target Met
12/SC/0434		(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	4	31/05/2015	Closed - Follow Up Complete	Target Met
14/WM/1228		CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric Study (BEAGLE)	13	31/05/2015	Withdrawn	Withdrawn
13/SC/0268		CCRN2100 (Cystic fibrosis)	3	31/07/2015	Closed - In Follow Up	Target Not Met
13/LO/0150		NCRN561 : The regorafenib in patients with hepatocellular carcinoma (RESORCE)	2	17/10/2015	Open	Still open to Recruitment
13/SW/0186		EFFECT - Efficacy of Fluticasone/Formoterol in COPD Treatment	4	31/08/2015	Withdrawn	Withdrawn
13/YH/0126		GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma	4	31/08/2015	Closed - In Follow Up	Target Not Met
13/EM/0149		15961 GadaCAD1	15	31/08/2015	Withdrawn	Withdrawn
14/EE/1063		AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy (AURA3)	3	02/09/2015	Closed - In Follow Up	Target Not Met
13/LO/0945		MCRN 2419: KOGNITO (Kuvan®'s effect on the cOGNITion of children with phenylketonuria)	2	30/09/2015	Open	Still open to Recruitment
13/EE/0367		CCRN 2215 (Crohn's)	3	30/09/2015	Open	Still open to Recruitment
14/SC/1014		CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma	2	30/09/2015	Open	Still open to Recruitment
13/LO/0161		MAESTRO: Macitentan in Eisenmenger Syndrome AC-055-305 (CCRN 2104)	3	01/10/2015	Open	Still open to Recruitment
13/LO/1283		MO 28037 - TAMIGA	6	30/10/2015	Closed - In Follow Up	Target Met
14/LO/1490		CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or stage IV Melanoma (CA209-172)	3	30/10/2015	Open	Still open to Recruitment
12/NW/0367		MCRN177 (BEL114055)	1	31/10/2015	Open	Still open to Recruitment
13/LO/0717		CL3-78989-006. EYEGUARD-C study	4	30/11/2015	Closed - Follow Up Complete	Target Met

Research Ethics Committee Reference	Study Title	Recruitment Target	Recruitment End Date	Study Status	Performance Against Target
14/EM/0034	NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO	2	30/11/2015	Closed - In Follow Up	Target Not Met
12/NW/0641	NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	9	01/12/2015	Closed - In Follow Up	Target Met
14/EM/0130	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy	2	01/12/2015	Open	Still open to Recruitment
13/WS/0304	EVARREST (The Fibrin Pad CV Phase III Study)	10	31/12/2015	Open	Still open to Recruitment
13/YH/0201	MCRN2280 Sativex Severe Spasticity (GWSP08258)	6	31/12/2015	Open	Still open to Recruitment
13/LO/1608	Study of efficacy and safety of nilotinib in paediatric CML patients	1	31/12/2015	Closed - In Follow Up	Target Met
14/YH/1124	EXTEND (2819MA1002)	3	31/12/2015	Open	Still open to Recruitment
14/SC/0181	Elagolix in Endometriosis Associated Pain - Extension	1	31/12/2015	Open	Still open to Recruitment
14/NI/1037	NCRN - 3245 - Betalutin radioimmunotherapy for treatment of relapsed CD37+ NHL	1	31/12/2015	Open	Still open to Recruitment
14/YH/1263	GLYSURE Study	10	31/12/2015	Open	Still open to Recruitment
14/YH/1090	QUIET-1	4	31/12/2015	Withdrawn	Withdrawn
14/LO/0036	NCRN2555 - TOWER Study (00103311)	5	31/01/2016	Closed - In Follow Up	Target Not Met
13/SC/0007	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma.	5	31/01/2016	Open	Still open to Recruitment
13/WM/0143	Study of Moxetumomab Pasudotox in pALL or LL of B-Cell	1	31/01/2016	Open	Still open to Recruitment
14/EM/0215	M12-914 Phase III Veliparib/Placebo + C/P Breast Cancer Study	1	29/02/2016	Open	Still open to Recruitment
15/SC/0242	HAEM 4448	1	29/02/2016	Open	Still open to Recruitment
15/NW/0573	CHIL4421 (NP25737)	1	16/03/2016	Open	Still open to Recruitment
12/SW/0084	LFG316 MFC	5	31/03/2016	Open	Still open to Recruitment
14/NI/1075	CHIL3670 (ALX0171-C104)	1	31/03/2016	Withdrawn	Withdrawn
13/WA/0101	CCRN 2088 (Pneumonia)	6	30/04/2016	Withdrawn	Withdrawn
14/YH/1037	MCRN3102 (SD653) Grunenthal Tapentadol Acute/Postoperative Pain (KF65)	4	13/05/2016	Open	Still open to Recruitment
14/YH/0007	MCRN2368 UCB PRA Epilepsy Lacosamide SP0969	2	24/05/2016	Withdrawn	Withdrawn
14/NW/0001	CCRN 2979 (Haemophilia A)	2	31/05/2016	Closed - In Follow Up	Target Met
14/WS/0004	CCRN 2825 (Hypercholesterolemia)	10	03/06/2016	Closed - In Follow Up	Target Met
13/EM/0012	NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with malignant melanoma	1	30/06/2016	Open	Still open to Recruitment
13/ES/0005	NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC)	2	30/06/2016	Open	Still open to Recruitment
13/LO/0716	CCRN 2159 (Uveitis)	4	30/06/2016	Withdrawn	Withdrawn
14/SC/1311	MCRN3165 (SD744) Cubist PSI Osteomyelitis	3	30/06/2016	Open	Still open to Recruitment
15/SC/0054	CheckMate 238 (Nivolumab vs Ipilimumab in Melanoma)	6	30/06/2016	Closed - In Follow Up	Target Not Met
14/YH/1269	CHIL3644 I.V. Tapentadol in post op pain	1	30/06/2016	Open	Still open to Recruitment
15/LO/0517	CANC - 4281 - YOSEMITE	5	30/06/2016	Open	Still open to Recruitment
14/LO/1617	GLP110933 study Type I DM Study (DRN 3266)	2	14/08/2016	Open	Still open to Recruitment
13/NW/0705	COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for resected liver metastases	7	31/08/2016	Open	Still open to Recruitment
13/NW/0002	CCRN 1073 (Thoracic aortic surgery)	15	30/09/2016	Open	Still open to Recruitment
11/SC/0173	VIABLE	6	16/10/2016	Open	Still open to Recruitment
14/SC/1425	CCRN 2738 (AMD)	7	31/10/2016	Open	Still open to Recruitment
15/NW/0009	MCRN3127 (20130173)	3	28/02/2017	Open	Still open to Recruitment
14/WM/0013	MCRN2947 (ALS-8176-503) Developing a new drug to treat infants hospitalised with RSV infection	8	30/04/2017	Open	Still open to Recruitment
11/LO/0923	NCRN259 HERBY - Bevacizumab in paediatric high grade glioma	3	22/08/2017	Closed - In Follow Up	Target Met

Performance Delivery Benchmark

Research Ethics Committee		Recruitment Target	Recruitment End Date	Study Status	Performance Against Target	
Reference	Study Title					
14/NE/0122	WA29231- LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS	1	30/09/2017	Open	Still open to Recruitment	
13/LO/0418	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	2	31/10/2017	Open	Still open to Recruitment	
14/NE/1099	GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS	1	31/12/2017	Open	Still open to Recruitment	
10/H0406/47	ABBOTT 327 CCRN 283 (LT uveitis)	8	31/03/2018	Open	Still open to Recruitment	